Abstract Anticoagulation for Subclinical Atrial Fibrillation Recently, the ARTESIA study addressed this question in a randomized trial of 4,012 patients with subclinical atrial fibrillation identified by an implanted device, and..
Read More
Abstract Background The management of hemostasis in patients medicated with apixaban (Eliquis) undergoing emergency cardiac surgery is exceedingly difficult. The body’s natural elimination pathways for apixaban prove ineffective in emergency..
Read More
Abstract What is known and objective Emergent cardiac surgery in patients under anticoagulant therapy is still a major point of concern. Recently approved reversal agents are often not available or..
Read More
Abstract Background: Patients on direct oral anticoagulants are at high risk of perioperative bleeding complicaapitions. We analyzed the results of intraoperative hemoadsorption (HA) in patients undergoing cardiac surgery who were..
Read More
Preamble Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and..
Read More
Abstract OBJECTIVES: The three direct oral anticoagulants (DOACs) dabigatran, apixaban and rivaroxaban are now widely used in clinical practice. For patients requiring perioperative interruption of DOACs, heparin bridging is still..
Read More
Abstract Case Report A 72-year-old man with a tachycardiomyopathy, atrium flutter, and atrial fibrillation underwent an elective radiofrequency ablation procedure. In addition to 5 mg of apixaban twice daily, his..
Read More
Bleeding Complications After Use of Novel Oral Anticoagulants in Patients Undergoing Cardiac Surgery
Abstract Background The study was performed to analyze the results of and bleeding complications after administration of novel (NOAC). Methods We investigated 81 consecutive patients (median age 74 years, interquartile range [IQR]:..
Read More